Discovery and evaluation of a novel ¹⁸F-labeled vasopressin 1a receptor PET ligand with peripheral binding specificity.

ABSTRACT: The arginine-vasopressin (AVP) hormone plays a pivotal role in regulating various physiological processes, such as hormone secretion, cardiovascular modulation, and social behavior. Recent studies have highlighted the V1a receptor as a promising therapeutic target. In-depth insights into V1a receptor-related pathologies, attained through in vivo imaging and quantification in both peripheral organs and the central nervous system (CNS), could significantly advance the development of effective V1a inhibitors. To address this need, we develop a novel V1a-targeted positron emission tomography (PET) ligand, [¹⁸F]V1A-2303 ([¹⁸F]8), which demonstrates favorable in vitro binding affinity and selectivity for the V1a receptor. Specific tracer binding in peri

SUBMITTER: Hu J 

PROVIDER: S-EPMC11413668 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature